Search Antibody Database

Found 1 matching record:

Displaying record number 2077

Download this epitope record as JSON.

MAb ID	3881
HXB2 Location	Env	Env Epitope Map
Author Location	gp120 (V3)
Epitope
Subtype	CRF02_AG
Ab Type	gp120 V3 // V3 glycan (V3g)
Neutralizing	tier 1 View neutralization details
Species (Isotype)	human(IgG1κ)
Patient
Immunogen	HIV-1 infection
Country	Cameroon
Keywords	antibody generation, antibody sequence, binding affinity, neutralization, structure, vaccine antigen design

Notes

Showing 3 of 3 notes.

3881: Neutralizing and binding activity of 18 anti-V3 MAbs from Cameroonian and Indian patients were compared. The Cameroonian patients had CRF02_AG (Env corresponding to clade A) and Indian patients had clade C. MAbs from Cameroonian patients were significantly more cross-neutralizing than those from India, suggesting the preference for CRF02_AG for vaccine design. This MAb was from patient from Cameroon and the subtype of the infecting virus was CRF02_AG. Andrabi2013 (neutralization)
3881: Two V3-scaffold immunogen constructs were designed and expressed using 3D structures of cholera toxin B (CTB), V3 in the gp120 context, and V3 bound to 447-52D MAb. The construct (V3-CTB) presenting the complete V3 was not recognized by 3881. 3881 also did not bind to the short V3-CTB construct, presenting a V3 fragment in conformation observed in complex with 447-52D. Totrov2010 (vaccine antigen design, binding affinity, structure)
3881: This Ab was derived from one of 12 individuals infected with non-B subtypes from Cameroon and India. The Ig usage for variable heavy chain of this Ab was as follows: IGHV:4-59*01, IGHD:2-2, D-RF:3, IGHJ:3. There was a preferential usage of the VH5-51 gene segment for V3 Abs. The usage of the VH4 family for the V3 Abs was restricted to only one gene segment, VH4-59, and the VH3 gene family was used at a significantly lower level by these Abs. The V3 Abs preferentially used the JH3 and D2-15 gene segments. Gorny2009 (antibody generation, antibody sequence)

References

Showing 3 of 3 references.

Isolation Paper
Gorny2009 Miroslaw K. Gorny, Xiao-Hong Wang, Constance Williams, Barbara Volsky, Kathy Revesz, Bradley Witover, Sherri Burda, Mateusz Urbanski, Phillipe Nyambi, Chavdar Krachmarov, Abraham Pinter, Susan Zolla-Pazner, and Arthur Nadas. Preferential Use of the VH5-51 Gene Segment by the Human Immune Response to Code for Antibodies against the V3 Domain of HIV-1. Mol. Immunol., 46(5):917-926, Feb 2009. PubMed ID: 18952295. Show all entries for this paper.

Andrabi2013 Raiees Andrabi, Constance Williams, Xiao-Hong Wang, Liuzhe Li, Alok K. Choudhary, Naveet Wig, Ashutosh Biswas, Kalpana Luthra, Arthur Nadas, Michael S. Seaman, Phillipe Nyambi, Susan Zolla-Pazner, and Miroslaw K. Gorny. Cross-Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from Non-B Clade HIV-1 Infected Individuals. Virology, 439(2):81-88, 10 May 2013. PubMed ID: 23466102. Show all entries for this paper.

Totrov2010 Maxim Totrov, Xunqing Jiang, Xiang-Peng Kong, Sandra Cohen, Chavdar Krachmarov, Aidy Salomon, Constance Williams, Michael S. Seaman, Ruben Abagyan, Timothy Cardozo, Miroslaw K. Gorny, Shixia Wang, Shan Lu, Abraham Pinter, and Susan Zolla-Pazner. Structure-Guided Design and Immunological Characterization of Immunogens Presenting the HIV-1 gp120 V3 Loop on a CTB Scaffold. Virology, 405(2):513-523, 30 Sep 2010. PubMed ID: 20663531. Show all entries for this paper.